There is a fundamental gap in understanding the impact of engineered nanomaterials (ENM) on the mononuclear phagocyte system (MPS), including Kupffer cells (KC) in the liver and antigen-presenting dendritic cells (DC) in the immune system. Our long-term goal is to develop a predictive 21st century toxicological platform for ENM safety assessment that is premised on cellular and organotypic cultures for high content screening, in which we will use adverse outcome pathways (AOPs) to derive structure-activity relationships (SARs) for toxicological profiling and decision analysis on consortium-provided ENMs. The overall objective is to use our mechanistic and high content screening approaches to perform hazard ranking, tiered risk assessment, and SAR analysis that link ENM physicochemical properties to AOPs in KC and DC, which is then used as the basis of in vivo predictions of the adverse impact on the liver and immune system. Our central hypothesis is that linkage of the ENM properties to molecular and pathophysiological alterations in the MPS will allow a mechanistic and high throughput approach for predicting the hazardous impact of ENMs on the MPS. The rationale of the proposed research is that the development of predictive and alternative testing platforms, including organotypic and cell co-culture models, will allow expedited risk assessment and categorization of broad ENM categories. Guided by our extensive experience for predictive toxicological modeling, we propose to explore the impact of the consortium-provided ENMs on the MPS in three specific aims:
Aim 1 : To use mechanistic, high content screening for hazard ranking and toxicological profiling of a diverse range of ENMs in KC and DC for SAR analysis and predictive toxicological profiling that can be used to plan studies in liver micro-tissues and animals.
Aim 2 : To use organotypic 3-D liver models, and limited in vivo toxicity assessment, imaging and biodistribution studies for toxicological profiling of a diverse range of related to toxicological injury pathways at the KC/hepatocyte interface and the liver of transgenic animals that express reporter genes (e.g., NF-?B).
Aim 3 : To use an antigen-specific (OVA peptide) dendritic and T-cell co-culture system and adoptive transfer in mice for toxicological and immunotoxicological profiling of a diverse range of ENMs, prior screened in Aim 1. Our approach is innovative, because of the substantive departure from the current status quo, where descriptive single agent toxicity testing will be replaced by rapid throughput, high content, and AOP-based predictive toxicological approaches for ENM effects on the MPS. The proposed research is significant because we will introduce mechanisms-based HTS approaches that can be used to link ENMs physicochemical properties to cellular and molecular response profiles for hazard profiling of intravenous injected ENMs. Not only will this provide a platform for expedited safety assessment of ENMs, but will also form the basis of extensive collaboration with the consortium, where predictive modeling can be used to study exposure systems such as the lung, GIT and the skin.
The proposed research is relevant to public health because the establishment of a robust scientific platform for safety assessment of engineered nanomaterials is required for risk assessment, enhancing worker and consumer safety, as well as identifying hazardous material properties that could be safer designed. Thus, the proposed research is relevant to the part of NIH's mission that pertains to reducing the burden of human illness and disability by understanding how a novel new technology can be safely implemented, including for the treatment of disease.
